within Pharmacolibrary.Drugs.ATC.R;

model R05DB17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.0004166666666666667,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.15,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0006666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R05DB17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Droxypropine is a non-opioid antitussive (cough suppressant) drug once used for the relief of dry, non-productive cough. It is classified under the ATC code R05DB17. Droxypropine is not commonly used or approved in current clinical practice and has limited recent literature or regulatory approval.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are not reported for droxypropine in the existing literature. The following values are rough estimates based on class similarity with other non-opioid antitussive agents in adult healthy subjects.</p><h4>References</h4><ol><li><p>Atkinson, HC, et al., &amp; Robson, R (2015). Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. <i>Clinical drug investigation</i> 35(10) 625–632. DOI:<a href=\"https://doi.org/10.1007/s40261-015-0320-8\">10.1007/s40261-015-0320-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26334726/\">https://pubmed.ncbi.nlm.nih.gov/26334726</a></p></li><li><p>Freedman, MD, &amp; Somberg, JC (1991). Pharmacology and pharmacokinetics of amiodarone. <i>Journal of clinical pharmacology</i> 31(11) 1061–1069. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1991.tb03673.x\">10.1002/j.1552-4604.1991.tb03673.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1753010/\">https://pubmed.ncbi.nlm.nih.gov/1753010</a></p></li><li><p>Chryssafidis, P, et al., &amp; Macheras, P (2021). Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations. <i>Pharmaceutical research</i> 38(8) 1345–1356. DOI:<a href=\"https://doi.org/10.1007/s11095-021-03078-w\">10.1007/s11095-021-03078-w</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34341958/\">https://pubmed.ncbi.nlm.nih.gov/34341958</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R05DB17;
